EP
MIRM icon

Essential Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Essential Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585 Hold
5
– – ﹤0.01% 2436
2026
Q1 		$462 Hold
5
– – ﹤0.01% 2459
2025
Q4 		$395 Sell
5
-2
-29% -$144 ﹤0.01% 2283
2025
Q3 		$513 Buy
7
+2
+40% +$127 ﹤0.01% 2199
2025
Q2 		$254 Buy
+5
New +$223 ﹤0.01% 1891

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's MIRM Position: Q2 2026 in Review

Essential Partners held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 5 shares worth $585. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Essential Partners first reported a position in MIRM in Q2 2025 and has held it in 5 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Essential Partners held 5 shares of Mirum Pharmaceuticals worth $585 as of Q2 2026.
  • Essential Partners left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
  • Mirum Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2436 holding.
  • Essential Partners first reported a position in Mirum Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.